Dezima Pharma - Articles and news items

Results from Phase 2b study of CETP inhibitor TA-8995 published

Industry news / 3 June 2015 / Victoria White

Dezima Pharma has announced the publication of the phase 2b TULIP study results with its CETP inhibitor, TA-8995, in patients with mild dyslipidaemia…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+